FDA staff say that Novo Nordisk's (NVO -3.4%) ultra long-acting insulin degludec appears to...

FDA staff say that Novo Nordisk's (NVO -3.4%) ultra long-acting insulin degludec appears to increase the risk of cardiovascular death, and non-fatal heart attacks, strokes and unstable angina by 30% relative to comparators, although the statistical uncertainty is large. An FDA advisory panel is due to vote on Thursday on whether to recommend the drug.
From other sites
Comments (4)
  • fernandomoz
    , contributor
    Comments (5) | Send Message
    since patients already frail-weak-due to their diabetes, any medicament besides the NVO treatment can be of greater risk for them than on a healthy person.
    As said the statistical uncertainty is HUGE.


    Dont forget Novo Norddisk is a european company, and there are lots
    of US companies trying to find equal medicaments .


    The FDA an american institution ,needs also look into their interests.


    Same happens in europe especially the french , always trying to defend their interests.


    George White
    6 Nov 2012, 09:59 AM Reply Like
  • CEO
    , contributor
    Comments (243) | Send Message
    whatever the politics, this can't bode well for NVO
    6 Nov 2012, 10:33 AM Reply Like
  • fernandomoz
    , contributor
    Comments (5) | Send Message
    U are correct shareprice dropped from 930 to 860 danish kroner
    6 Nov 2012, 03:02 PM Reply Like
  • murlan
    , contributor
    Comments (30) | Send Message
    It is down quite a bit on this news. Doesn't change the fundamental fact that they are the largest company in diabetes care and that market will continue to grow rapidly. If they were a buy at 160, it seems they are more of a buy today. Only question is how low it falls before establishing a new base.
    6 Nov 2012, 01:30 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs